Discover
NNNN
Anbio Biotechnology Class A Ordinary Shares
10.17
1 x 9.90
1 x 10.60
bid
ask
-
0.02
0.20%
12:33 PM
timesize
| Ytd | -66.18% | |
| 1y | -78.38% |
10.00
day range
10.64
8.30
52 week range
54.95
| Open | 10.64 | Prev Close | 10.19 | Low | 10.00 | High | 10.64 | Mkt Cap | 446.37M |
| Vol | 10.98K | Avg Vol | 41.34K | EPS | 0.07 | P/E | 146.97 | Forward P/E | N/A |
| Beta | 5.40 | Short Ratio | 1.79 | Inst. Own | 4.90% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-28 | 50-d Avg | 14.37 | 200-d Avg | 23.72 | 1yr Est | 0.00 |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|
Profile
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets. Anbio Biotechnology was incorporated in 2021 and is based in Frankfurt am Main, Germany.
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | Geode Capital Management, LLC | 25.76K | 241.91K | 0.06% |
| 2026-03-30 | BNP Paribas Financial Markets | 10.40K | 97.66K | 0.02% |
| 2026-03-30 | Morgan Stanley | 7.34K | 68.90K | 0.02% |
| 2026-03-30 | UBS Group AG | 6.34K | 59.52K | 0.01% |
| 2026-03-30 | Blue Trust, Inc. | 5.00 | 46.00 | 0.00% |
| 2026-03-30 | Wells Fargo & Company | 100.00 | 939.00 | 0.00% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-05-30 | Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 26.74K | 251.05K | 0.06% |